Compare Fiverr International Ltd (FVRR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Fiverr International Ltd trades at $11.72 (market cap $404.45M), while Recursion Pharmaceuticals Inc trades at $3.15 (market cap $1.75B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.3× Fiverr International Ltd's market cap. Which is the better fit depends on your goals.
| FVRR | RXRX | |
|---|---|---|
Market Cap | $404.45M | $1.75B |
Sector | Industrials | Health |
52-Week High | $26.67 | $6.79 |
52-Week Low | $9.62 | $2.84 |
Enterprise Value | $135.05M | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.07, down 1.77% on the day, with a bullish technical signal from moving averages. The company reported revenue of $430.91M in 2025, with net income of $20.98M and improving profit margins. Recent earnings show a mix of beats and one miss, with Q2 2026 results expected soon. Analyst sentiment is mixed, with 41.18% buy ratings and no sell ratings.
The outlook hinges on execution of its strategy shift amid competitive pressures. Risks include declining active buyers and a pending legal investigation. Upside potential exists if spending per buyer growth continues and the company returns to consistent earnings beats, but investor caution is warranted near the 52-week low.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
